| dc.description.abstract | Aims: The aim of the present study was to critically review the available published literature regarding the use of Parodontax® herbal toothpaste formulations and to determine whether there was supportive evidence for the safety and clinical efficacy of Parodontax® toothpaste formulations for the reduction in plaque growth and on gingival inflammation. Methods: A manual and electronic literature search (MEDLINE and Cochrane Central Register of Controlled Trials) was performed up to February 2015, for randomised controlled trials (RCT) presenting clinical, microbiological, immunological, and patient-centred data for the efficacy of Parodontax® in controlling both plaque and gingival inflammation. Results: From 111 titles and abstracts, 104 were excluded and from the full text articles screened, seven randomized controlled trials were selected. Two of the included randomized controlled trials reported that Parodontax® toothpastes were similar in efficacy to the control dentifrices in effectively reducing both plaque and gingival inflammation in patients with gingivitis based on the assessment criteria of clinical, microbiological, and patient-centred treatment outcomes. Four of the included studies reported a significant effect of Parodontax® however there was a lack of clarity in the reporting of measures e.g., appropriate randomisation, calibration, blinding, and the outcomes assessed, and as such, the quality of both reporting and methodology may have been flawed with a high risk of bias. Conclusion: The results from the published literature regarding the safety and clinical effectiveness of Parodontax ® toothpaste would indicate that while the toothpaste has some short-term effects on both plaque and gingival inflammation, further studies are required to determine its effectiveness as an anti-gingivitis agent over six months. | en_US |
